ライフサイエンスコーパス: alloreactive

1 ese findings dovetail with recent studies of alloreactive and autoimmune TCRs and suggest that the bi

2 stress plays a key role in the activation of alloreactive and autoreactive immunity toward the engraf

3 Thus, the requirements for tolerizing alloreactive and autoreactive NOD CD4 cells are distinct

4 egs) control the activation and expansion of alloreactive and autoreactive T cell clones.

5 ional mechanism for activating and expanding alloreactive and autoreactive T cells.

6 Here, we demonstrate that alloreactive and nonalloreactive TCR differ specifically

7 Instead, macrophages become alloreactive and readily recognize and reject allogeneic

8 Alloreactive antibodies were solely found in dexDC-treat

9 was used to monitor glucose, C-peptide, and alloreactive antibodies.

10 led that, despite fundamental differences in alloreactive B cell fates in sensitized versus naive rec

11 plant immunology has been on controlling the alloreactive B cell population, long-term transplant pat

12 ng cells and by actively suppressing de novo alloreactive B cell responses.

13 Unexpectedly, dysfunctional alloreactive B cells acquired the ability to inhibit ant

14 Thus, tolerant alloreactive B cells contribute to transplantation toler

15 for the identification of comparable memory alloreactive B cells in transplant recipients.

16 We inferred that tolerant alloreactive B cells retained their ability to sense all

17 hiew et al. investigated the contribution of alloreactive B cells to transplantation tolerance using

18 ine model of heart tolerance, we showed that alloreactive B cells were not deleted but rapidly lost t

19 ing tools to monitor donor-specific B cells, alloreactive B cells were shown to increase in accordanc

20 steps that are involved in the generation of alloreactive B cells, with a specific emphasis on how kn

21 rease in the activation and proliferation of alloreactive CD4 and CD8 T cells after transplantation a

22 Alloreactive CD4 T cell-mediated MVEC death involves TNF

23 In vitro, alloreactive CD4 T cells were competent to lyse donor ma

24 Alloreactive CD4 T cells were isolated from peripheral b

25 visualization of the fate of TCR-transgenic alloreactive CD4(+) and CD8(+) T cells after encounterin

26 reveal parallel roles for Notch signaling in alloreactive CD4(+) and CD8(+) T cells that differ from

27 e studied the effects of Notch inhibition in alloreactive CD4(+) and CD8(+) T cells using mouse model

28 rolling proliferation and differentiation of alloreactive CD4(+) conventional T cells in draining lym

29 However, Notch-deprived alloreactive CD4(+) T cells retained significant cytotox

30 Anti-CD20 Ab had a major effect on alloreactive CD4(+) T cells, increasing the expansion of

31 T cells increased IFN-gamma production from alloreactive CD4(+) T cells, whereas blockade of dendrit

32 g of Treg, which diminished proliferation of alloreactive CD4(+) T cells.

33 immunotherapy is limited by the increase in alloreactive CD4(+) T lymphocytes.

34 Alloreactive CD4CD45RA/CD45RO T cells generated in 9-day

35 ioresistant immune cells in GVHD recipients, alloreactive CD62L(-) T cells lost the reactivity over t

36 multaneously present it as intact protein to alloreactive CD8 T cells and as processed peptide alloan

37 the magnitude, diversity, and specificity of alloreactive CD8 T cells in patients who developed GVL r

38 hown to provide strong activating signals to alloreactive CD8 T cells while avoiding changes in natur

39 on therapy and had a substantial increase in alloreactive CD8 T cells with a CD28/DR/CD38/CD45RO TEM.

40 h B cells expressing Patr-AL produced potent alloreactive CD8 T cells with specificity for Patr-AL an

41 Alloreactive CD8 T effector (Teff) activation and T memo

42 Although B cells were important for optimal alloreactive CD8 Teff/Tmem function in the sensitization

43 se recipients, the rejection was mediated by alloreactive CD8(+) T cells presumably primed in the bon

44 ulting in reduced frequencies of circulating alloreactive CD8(+) T cells.

45 ated that CD27low NK cells directly regulate alloreactive CD8+ Tcell responses under costimulatory bl

46 WT recipients of these alloreactive cells developed anti-dsDNA autoantibodies s

47 ble to drive proliferation of autologous and alloreactive conventional T cells, as seen with B cells

48 The alloreactive CTL precursor (CTLp) frequency was determin

49 that irradiated allografts did not elicit an alloreactive delayed-type hypersensitivity response in g

50 However, perforin-deficient alloreactive DLI induced significantly less apoptosis of

51 Alloreactive DNMAML T cells exhibited decreased Ras/MAPK

52 arenchymal cells controls the second wave of alloreactive donor CD8(+) T cell expansion and the assoc

53 aft-versus-host disease (GVHD), triggered by alloreactive donor cells, has remained a major complicat

54 Efforts to limit GVHD mediated by alloreactive donor T cells after allogeneic bone marrow

55 Alloreactive donor T cells against host minor histocompa

56 ighlight CNS sensitivity to damage caused by alloreactive donor T cells and represent the first chara

57 Alloreactive donor T cells are the driving force in the

58 Alloreactive donor T cells attack leukemia cells, mediat

59 Alloreactive donor T cells can damage thymic epithelium,

60 by extensive activation and proliferation of alloreactive donor T cells causing significant morbidity

61 PD-1H coinhibitory receptor potently arrests alloreactive donor T cells from activation and expansion

62 ggest that infusion of sufficient numbers of alloreactive donor T cells will induce GVHD in the absen

63 y antigen-presenting cells (APCs) that prime alloreactive donor T cells.

64 sease (GVHD) is initiated by APCs that prime alloreactive donor T cells.

65 )FOXP3(+)) through the in vivo conversion of alloreactive donor T effectors (Teffs; CD4(+)CD25(-)FOXP

66 ectively protects against GVHD by modulating alloreactive donor T-cell responses, and that CXCR3 sign

67 energetics profile analysis of proliferating alloreactive donor T-cells demonstrated increased aerobi

68 oreover, under IL-4 neutralizing conditions, alloreactive double-deficient T cells upregulated Eomeso

69 A significant fraction of alloreactive Drak2-/- T cells underwent apoptosis follow

70 ves the rapid rejection of the NE-CBU, whose alloreactive effect might also contribute to graft-versu

71 an allograft via the differential control of alloreactive effector and regulatory T cell survival.

72 Alloreactive effector CD4(+) T cells toward 1 or more mi

73 hylation leads to selective apoptosis of the alloreactive effector cells.

74 Here, we demonstrate that alloreactive effector T cells (Teff) use fatty acids (FA

75 e preserving GVL by peripheral conversion of alloreactive effector T cells into FOXP3(+) Tregs and ep

76 vivo administration of Dll4 Ab reduced donor-alloreactive effector T cells producing IFN-gamma and IL

77 Alloreactive effector T cells that expanded in the absen

78 CD19-specific (CD19-CAR) T cells possessing alloreactive endogenous T-cell receptors.

79 e-antigen antibody testing, autoreactive and alloreactive flow cytometry crossmatches (FXM) using tra

80 essing clonal anti-H2K T cell receptor (TCR) alloreactive for MHC I, graft survival was significantly

81 the most potent at inducing high numbers of alloreactive Foxp3(+) cells.

82 per T-cell increases, elevated antiviral and alloreactive functional responses, and significantly gre

83 both T-bet and RORgammat differentiated into alloreactive GATA-3-expressing Th2 cells, which promptly

84 derstanding of the fate and function of both alloreactive graft-deteriorating T cells and those prote

85 geneic immunity, with complete prevention of alloreactive H-Y Ab development in male patients with fe

86 between CBUs in dUCBT, we hypothesized that alloreactive HLA class II-specific CD4(+) T cells from t

87 Consequently, alloreactive HLA-A2-specific cytotoxic T cells failed to

88 HLA-DP surface expression and recognition by alloreactive human CD4 T cells.

89 beta-cells in the absence or presence of an alloreactive human immune system.

90 mechanisms associated with their actions on alloreactive human T cells are not fully understood.

91 as associated with an increased frequency of alloreactive IFN-gamma-, IL-4-, and IL-6-producing splen

92 was accompanied by increased frequencies of alloreactive IFN-gamma-, IL-6-, and IL-17-producing sple

93 ted a standard operating procedure (SOP) for alloreactive IFNgamma ELISPOT assays in several research

94 from endothelial cells to selectively expand alloreactive IL-18R1+ T peripheral helper cells in allog

95 been identified that can be used to suppress alloreactive immune cells and prevent lethal GVHD in mic

96 e requires elimination and/or suppression of alloreactive immune cells.

97 VHD without altering the load or function of alloreactive immune cells.

98 y, cellular therapy for GVHD will not affect alloreactive immune responses against tumor cells.

99 lerogenic cytokine that efficiently inhibits alloreactive immune responses and mediates transplant to

100 f the potential importance of fetal-specific alloreactive immune responses within disorders of pregna

101 h CD8+ and CD4+ Tregs and markedly inhibited alloreactive immune responses.

102 survival by inhibiting the proliferation of alloreactive interferon-gamma+CD8+ T cells.

103 C5aR signaling on induction and stability of alloreactive iTreg.

104 cell transplantation in which donor-derived (alloreactive) KIR2DS1(+) NK cells, upon CCR7 acquisition

105 proinflammatory cytokines, and expansion of alloreactive luc-transgenic T cells.

106 cells resist cellular rejection by targeting alloreactive lymphocytes in vitro and in vivo, while spa

107 cally, a transient reversal in the anergy of alloreactive lymphocytes is seen in parallel with the gl

108 s dependent on the frequency and function of alloreactive lymphocytes, making the identification and

109 timulatory blockade conditions by regulating alloreactive memory CD8+ T-cell responses.

110 et-/- recipients showed strikingly increased alloreactive memory CD8+ Tcell responses, as indicated b

111 Alloreactive memory cells can mount rapid and robust res

112 Alloreactive memory helper T cells can induce potent all

113 blockade regimen suppressed proliferation of alloreactive memory T cells and attenuated their cytokin

114 Recent evidence suggests that alloreactive memory T cells are generated by the process

115 stant rejection and specifically the role of alloreactive memory T cells in mediating this resistance

116 The presence of alloreactive memory T cells is a major barrier for induc

117 e efficacy of the regimen, since preexisting alloreactive memory T cells might be stimulated by the t

118 Alloreactive memory T cells play a key role in transplan

119 Alloreactive memory T cells prevent costimulatory blocka

120 cell responses and long-term persistence of alloreactive memory T cells specific for the tumor, ofte

121 was able to suppress cytokine production by alloreactive memory T cells that was resistant to belata

122 To compare the fates of alloreactive naive (T(N)) or memory (T(M)) T cells, we d

123 Alloreactive natural killer (NK) cells can be recruited

124 V-1 transmission and that this may be due to alloreactive NK cell killing of the HIV-1-infected partn

125 In conclusion, KIR2DS2 identifies potent alloreactive NK cells against GBM that are mediated by c

126 will inform strategies to develop functional alloreactive NK cells for therapeutic use.

127 egulated inflammatory cytokine production by alloreactive NK cells in response to infectious challeng

128 , rapid killing of donor lymphocytes by host alloreactive NK cells is essential.

129 d hematopoietic stem cell transplants induce alloreactive NK cells, which prevent leukemia relapse.

130 These findings suggest that alloreactive passenger B cells/plasma cells within the k

131 It is also effective in depleting both alloreactive plasma cells in acute Ab-mediated transplan

132 It results from alloreactive processes induced by minor MHC incompatibil

133 In addition, hPB-MSCs suppressed alloreactive proliferation as well as the production of

134 d that this antitumor effect was mediated by alloreactive rather than EBV-specific T cells.

135 e that within the functionally heterogeneous alloreactive repertoire, there is the potential for high

136 d mononuclear cells (PBMC) and the resultant alloreactive response studied.

137 ensors, effectors, suppressors of the immune alloreactive response, and the resultant tissue damage f

138 of suppression utilised by Tregs to control alloreactive responses are ongoing.

139 yclophosphamide (pt-Cy) effectively prevents alloreactive responses from unmanipulated grafts, but it

140 ore and after HCV eradication and quantified alloreactive responses using cell lines expressing singl

141 eptors such as CCR5 plays a critical role in alloreactive responses, and previous data suggest that C

142 respectively, which allowed us to study the alloreactive role of each subset in an experimental tran

143 Although simple alloreactive rules have been established for inhibitory

144 ts; however, although TR cells proved highly alloreactive, SE cells showed a favorable safety profile

145 Importantly, also putatively alloreactive single KIR(+) NK cells were eliminated by P

146 l tolerance was caused by clonal deletion of alloreactive specificities from the primary B cell reper

147 d developing approaches to track and analyze alloreactive T and B cells in mice and humans and provid

148 s, making the identification and analysis of alloreactive T and B cells in transplant recipients crit

149 models, which implicates clonal deletion of alloreactive T and B cells, induction of cell-intrinsic

150 a proinflammatory gene program that enhances alloreactive T cell activation and development of cardia

151 gated by the presence of anti-K(d) mAbs, and alloreactive T cell activation as well as acute rejectio

152 Current therapies to prevent alloreactive T cell activation largely cause generalized

153 PD-1 signaling inhibits alloreactive T cell activation, and can promote induced

154 ss damage inflicted exclusively by DSAs when alloreactive T cell and B cell responses coincide.

155 opoietic cells is involved in the control of alloreactive T cell apoptosis and expansion.

156 oreover, PDL1 blockade inhibited Ag-specific alloreactive T cell apoptosis and induced apoptosis of T

157 The repertoire of alloreactive T cell clones is distinct for every donor-r

158 cient together but not separately to achieve alloreactive T cell dysfunction, and conventional immuno

159 y challenge previous reports indicating that alloreactive T cell elimination and thymic clonal deleti

160 in vivo proliferation but preserved overall alloreactive T cell expansion while enhancing accumulati

161 ed a low-fat diet, correlating with enhanced alloreactive T cell function.

162 Lm infection after tolerance did not rescue alloreactive T cell memory differentiation or functional

163 The size and diversity of the HLA-alloreactive T cell repertoire has thus far precluded th

164 associated with a lack of a proinflammatory alloreactive T cell response and an activation/expansion

165 The factors that drive the alloreactive T cell response are not completely understo

166 ation of donor DCs efficiently initiates the alloreactive T cell response that causes acute rejection

167 reof we demonstrated that the attenuation of alloreactive T cell responses after G-CSF mobilization r

168 By separating these seemingly similar alloreactive T cell responses based on the context of in

169 Accordingly, these mice restricted alloreactive T cell responses during graft-versus-host r

170 cure hematological malignancies by inducing alloreactive T cell responses targeting minor histocompa

171 Mismatched HLA-DP is targeted by direct alloreactive T cell responses with important implication

172 ding posing an autoimmune hazard, dominating alloreactive T cell responses, inducing allergy, and exp

173 h its phenotype and suppression of antidonor alloreactive T cell responses.

174 D4(+) Tregs and potently suppressed in vitro alloreactive T cell responses.

175 Previously, we found that alloreactive T cell targeting of GVL-sensitive bcr-abl-i

176 s among T(N) and T(M), and to track fates of alloreactive T cells after transplantation.

177 pient lymphoid tissues and directly activate alloreactive T cells against donor MHC molecules.

178 -gamma-deficient donor T cells, or depleting alloreactive T cells all compromised intratumoral IFN-ga

179 for the potentially different frequencies of alloreactive T cells among T(N) and T(M), and to track f

180 mice, enhanced the ability of APCs to prime alloreactive T cells and accelerated graft rejection, su

181 unded by effector mechanisms of uncontrolled alloreactive T cells and anti-HLA antibodies.

182 Alloreactive T cells and anti-human leukocyte antigen an

183 Integrin-mediated adhesion between alloreactive T cells and antigen-presenting cells is ess

184 sentation of donor MHC molecules to directly alloreactive T cells and delayed graft rejection in mice

185 In cGVHD, alloreactive T cells and germinal center (GC) B cells of

186 This amplifies the activation of alloreactive T cells and increases the severity of GVHD.

187 ction of PD-1H as a coinhibitory receptor on alloreactive T cells and its function in the regulation

188 IL-6 IMB group contained significantly fewer alloreactive T cells and macrophages.

189 neic BM transplantation tolerizes peripheral alloreactive T cells and permits establishment of mixed

190 vation of DN T cells specifically suppressed alloreactive T cells and prevented the development of gr

191 cells are thought to control the priming of alloreactive T cells and the induction of acute GVHD aft

192 is PD-1(Hi)ROS(Hi) phenotype was specific to alloreactive T cells and was not observed in syngeneic T

193 vestigate whether memory can be induced when alloreactive T cells are activated in the setting of tol

194 Alloreactive T cells are crucial for graft-versus-host d

195 review will identify the mechanisms by which alloreactive T cells arise within hosts prior to transpl

196 it has been difficult to selectively delete alloreactive T cells because the majority of protocols e

197 t singularly dependent on depletion of donor alloreactive T cells but also requires rapidly recoverin

198 de of FA oxidation decreased the survival of alloreactive T cells but did not influence the survival

199 indicate that PD-1 facilitates apoptosis in alloreactive T cells by increasing ROS in a process depe

200 ithymocyte globulin facilitates apoptosis of alloreactive T cells by means of caspase-3 activation, w

201 Thus in GVHD, alloreactive T cells can be activated when pathways crit

202 Selective depletion of the alloreactive T cells causing graft-versus-host disease (

203 We found that both murine and human alloreactive T cells concomitantly upregulated PD-1 expr

204 emory T cells provide help for activation of alloreactive T cells despite the costimulatory blockade.

205 We demonstrate that alloreactive T cells expressing CD28-costimulated CD19 C

206 rvous system (CNS) can be a direct target of alloreactive T cells following allo-HSCT in mice.

207 Heterologous memory alloreactive T cells generated by infections prior to tr

208 ctions, as effector, regulatory, memory, and alloreactive T cells have distinct metabolic needs in im

209 irmed in four others, PTCy did not eliminate alloreactive T cells identified using either specific Vb

210 eic antigens and activate both CD4+ and CD8+ alloreactive T cells in an MHC-restricted fashion.

211 PD-1H may be a target for the modulation of alloreactive T cells in GVHD and transplantation.

212 igated the impact of donor NK cells on donor alloreactive T cells in GVHD induction.

213 ys can provide a new window into the fate of alloreactive T cells in human transplant recipients.

214 rkedly increased accumulation of DLI-derived alloreactive T cells in parenchymal GVHD target tissues.

215 tch inhibition decreased the accumulation of alloreactive T cells in the intestine, a key GVHD target

216 Spi6(-/-) nTregs and impaired suppression of alloreactive T cells in vitro.

217 Alloreactive T cells increased FA transport, elevated le

218 In hematopoietic cell transplants, alloreactive T cells mediate the graft-versus-leukemia (

219 D, novel strategies that selectively deplete alloreactive T cells or modulate the balance of effector

220 ifferential susceptibility of proliferating, alloreactive T cells over nonproliferating, nonalloreact

221 We show alloreactive T cells persist after induction of cardiac

222 In addition, alloreactive T cells primed in the absence of Notch sign

223 splant studies indicate that GVHD-initiating alloreactive T cells reside primarily in naive and centr

224 Alloreactive T cells target their inducing alloantigens

225 rdiac allograft vasculopathy lesions contain alloreactive T cells that secrete interferon-gamma, a va

226 fts associated with impaired localization of alloreactive T cells to heart grafts.

227 Attempts to manipulate alloreactive T cells to spare normal cells while killing

228 al and fluorescent microscopy, we found that alloreactive T cells traffic distinctly into the toleran

229 inflamed endothelium, is important for donor alloreactive T cells trafficking into GVHD target organs

230 whether PTCy works singularly by eliminating alloreactive T cells via DNA alkylation or also by resto

231 In vivo expansion of alloreactive T cells was diminished while displaying a T

232 Lymphoid neogenesis containing alloreactive T cells was observed in the lungs, which re

233 lerance induction mainly focus on inhibiting alloreactive T cells while promoting regulatory immune c

234 in which we were able to selectively deplete alloreactive T cells with an indirect specificity by tar

235 and IFNgamma production, by naive and memory alloreactive T cells, and observed an increased frequenc

236 he degree of antigen specificity mediated by alloreactive T cells, and their ability to discriminate

237 ocalization of alloantigen-presenting cells, alloreactive T cells, and Tregs.

238 Therefore, direct priming of alloreactive T cells, as well as rejection and regulator

239 se inhibitors can block all Notch signals in alloreactive T cells, but lead to severe on-target intes

240 PT-Cy selectively eliminates proliferating alloreactive T cells, but whether and how it affects nat

241 d decreased IFN-gamma and IL-4 production by alloreactive T cells, especially when combined with depl

242 2 ablation retained antileukemia activity in alloreactive T cells, leading to improved overall surviv

243 in T-cell allografts attenuates expansion of alloreactive T cells, leading to lower GVHD.

244 Thus, although TAC inhibits all alloreactive T cells, SRL promotes the differentiation a

245 t murine TRAIL+ T cells induced apoptosis of alloreactive T cells, thereby reducing GVHD in a DR5-dep

246 ost disease (GVHD) is initially triggered by alloreactive T cells, which damage peripheral tissues an

247 MEK inhibitors would preferentially inhibit alloreactive T cells, while sparing more differentiated

248 -mediated suppression and thymic deletion of alloreactive T cells.

249 genic profile and inhibited proliferation of alloreactive T cells.

250 se herbs for their ability to suppress human alloreactive T cells.

251 questration of IL-2 produced by conventional alloreactive T cells.

252 but decreased the functional activity of the alloreactive T cells.

253 ng in vivo prevented miR-214 upregulation in alloreactive T cells.

254 ate the CD40-CD154-independent activation of alloreactive T cells.

255 an endothelial cells to recruit and activate alloreactive T cells.

256 ction via direct cytotoxicity and priming of alloreactive T cells.

257 e of Notch ligands during in vivo priming of alloreactive T cells.

258 VL) effect that is mediated by donor-derived alloreactive T cells.

259 enting cells (APCs) and decreased priming of alloreactive T cells.

260 llenges, and recent advances in the study of alloreactive T cells.

261 e activated and triggered full activation of alloreactive T cells.

262 ceiving heart allografts have suppression of alloreactive T effector cells and delayed acute rejectio

263 AAT treatment reduced the expansion of alloreactive T effector cells but enhanced the recovery

264 bitors and uncontrolled effector function of alloreactive T lymphocytes are main drivers of transplan

265 Alloreactive T lymphocytes are the primary mediators of

266 that disrupts essential signals required for alloreactive T-cell activation.

267 Alloreactive T-cell apoptosis may explain reduced immuno

268 and incubated with either indirect or direct alloreactive T-cell clones.

269 to test the putative underlying mechanisms: alloreactive T-cell elimination, alloreactive T-cell int

270 , LFA-1 blockade inhibits initial endogenous alloreactive T-cell expansion and induces more regulatio

271 Rather, PTCy induced alloreactive T-cell functional impairment which was supp

272 anti-human leukocyte antigen antibodies, and alloreactive T-cell immunity (interferon-gamma ELISPOT)

273 mechanisms: alloreactive T-cell elimination, alloreactive T-cell intrathymic clonal deletion, and sup

274 ay CD4 T cells are likely to be the dominant alloreactive T-cell population late after transplantatio

275 esulted in decreased T-cell infiltration and alloreactive T-cell priming as well as improved function

276 S did not directly interfere with vigorously alloreactive T-cell proliferation in vivo and in vitro.

277 how no effect on moDC maturation/activation, alloreactive T-cell proliferation, Treg expansion, or al

278 se of CsA to the culture medium, suppressing alloreactive T-cell proliferation.

279 re directly demonstrated by expansion of the alloreactive T-cell repertoire through the addition of p

280 ctor composition of both ones protective and alloreactive T-cell repertoire.

281 o T cells, thus causing the equivalent of an alloreactive T-cell response.

282 T cells may underlie its ability to inhibit alloreactive T-cell responses after transplantation.

283 erum levels of HS, leading to a reduction in alloreactive T-cell responses and GVHD severity.

284 nor-derived DCs, which otherwise would prime alloreactive T-cell responses.

285 ing the negative role of B7-H4 in regulating alloreactive T-cell responses.

286 enhancement of dendritic cell maturation and alloreactive T-cell responses.

287 asing interest in the monitoring of indirect alloreactive T-cells.

288 ystem that could be used to monitor indirect alloreactive T-cells.

289 d cytotoxic T lymphocyte-mediated killing of alloreactive target cells.

290 gulating the differentiation and function of alloreactive Tc cells in vitro was explored by stimulati

291 Here, we show how an alloreactive TCR achieves peptide and MHC specificity.

292 s help explain the paradox of specificity in alloreactive TCRs and have implications for their use in

293 in unclear, the existence of highly specific alloreactive TCRs has led to their use as immunotherapeu

294 indicating that additional pathways restrain alloreactive TEM TS1 TN also caused more severe GVHD wit

295 1c-specific Rictor(-/-) mice, we confirm the alloreactive Th1 and Th17 cell-polarizing ability of end

296 maturation and suppressing the generation of alloreactive Th1 immunity.

297 n WT, in vivo cytotoxic activity analysis of alloreactive Tmem recall response has revealed decreased

298 erent affinity for MHC, most T cells are not alloreactive to a given MHC.

299 s educated on these mutant MHC molecules are alloreactive to each other and to WT cells, and vice ver

300 FK506, GNF362 more selectively deleted donor alloreactive vs nominal antigen-responsive T cells.